A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison with existing assays - 09/06/12
, John J. Zaunders b , Marshall Plit d, e , Craig Leeman d , Susanna Ip b , Thatri Iampornsin c , Sarah L. Pett a, d , Michelle Bailey b , Janaki Amin a , Sasiwimol Ubolyam c , Anchalee Avihingsanon c, f , Jintanat Ananworanich c, f , Kiat Ruxrungtham c, f , David A. Cooper a, b , Anthony D. Kelleher a, b 
Corresponding author. St Vincent’s Centre for Applied Medical Research Lowy-Packer Building, Level 9, 405 Liverpool Street, Darlinghurst, NSW 2010, Australia. Tel.: +61 2 8382 4941; fax: +61 2 8382 4967.Summary |
A strategy to reduce the burden of active TB is isoniazid preventive therapy for latent TB infection (LTBI). However, current assays used to diagnose LTBI all have limitations.
In these proof of concept studies, we compared the agreement of a novel flow cytometry assay detecting CD25/CD134 co-expression with QuantiFERON-TB Gold In-Tube (QFN-GIT) and Tuberculin skin test (TST) in the detection of recall immune response to TB.
The CD25/CD134 assay, QFN-GIT and TST were performed on 74 participants referred for TB screening in Sydney and on 50 participants with advanced HIV infection (CD4 ≤ 350 × 106 cells/L) in Bangkok.
The agreement between CD25/CD134 assay and QFN-GIT was 93.2% (Kappa 0.631 95% CI 0.336–0.926) in Sydney and 90% (Kappa 0.747 95% CI 0.541–0.954) in Bangkok. Discordant results occurred around the cut off of both tests.
The agreement between CD25/CD134 assay and TST was 73.6% (Kappa 0.206 95% CI 0.004–0.409) in Sydney and 84% (Kappa 0.551 95% CI 0.296–0.806) in Bangkok.
The CD25/CD134 assay showed good agreement with QFN-GIT in detecting recall response to TB both in well and less resourced setting as well as in persons with advanced HIV infection. Further study into the performance of this assay is thus warranted.
Le texte complet de cet article est disponible en PDF.Keywords : Mycobacterium tuberculosis, Antigen specific CD4, CD134, CD25, Quantiferon gold in tube
Plan
Vol 92 - N° 4
P. 321-327 - juillet 2012 Retour au numéro
Article précédent
- Point-of-care breath test for biomarkers of active pulmonary tuberculosis
- Michael Phillips, Victoria Basa-Dalay, Jaime Blais, Graham Bothamley, Anirudh Chaturvedi, Kinjal D. Modi, Mauli Pandya, Maria Piedad R. Natividad, Urvish Patel, Nagsen N. Ramraje, Peter Schmitt, Zarir F. Udwadia
- Mycobacterium tuberculosis WhiB1 represses transcription of the essential chaperonin GroEL2
- Melanie R. Stapleton, Laura J. Smith, Debbie M. Hunt, Roger S. Buxton, Jeffrey Green
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?